Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
US Department of Justice
Mallinckrodt
Julphar
Daiichi Sankyo
Accenture
Chubb
Cantor Fitzgerald
US Army

Generated: May 25, 2018

DrugPatentWatch Database Preview

TOLECTIN DS Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Tolectin Ds patents expire, and when can generic versions of Tolectin Ds launch?

Tolectin Ds is a drug marketed by Ortho Mcneil Janssen and is included in one NDA.

The generic ingredient in TOLECTIN DS is tolmetin sodium. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the tolmetin sodium profile page.
Summary for TOLECTIN DS
Drug patent expirations by year for TOLECTIN DS
Medical Subject Heading (MeSH) Categories for TOLECTIN DS
Synonyms for TOLECTIN DS
1-Methyl-5-(p-toluoyl)-2-pyrroleacetic acid
1H-Pyrrole-2-acetic acid, 1-methyl-5-(4-methylbenzoyl)-, sodium salt
1H-Pyrrole-2-acetic acid, 1-methyl-5-(4-methylbenzoyl)-, sodium salt, dihydrate
1H-Pyrrole-2-acetic acid, 1-methyl-5-(p-toluoyl)-, sodium salt
1H-Pyrrole-2-aceticacid, 1-methyl-5-(4-methylbenzoyl)-, sodium salt (1:1)
26171-23-3 (Parent)
35711-34-3
AB01566945_01
AC-12807
ACM35711343
AK129821
AKOS015901707
AKOS015961034
API0016245
AX8154346
C02328
C15H14NO3.H2O.Na
C15H14NO3.Na
CCG-39123
CHEBI:9619
CHEMBL1200613
CTK4H5216
DTXSID2091546
EINECS 252-687-3
HE057302
HE329759
HMS1921E19
HMS2092O03
HMS500K15
I14-13943
KB-259743
KB-61756
LS-136617
LS-136619
McN-2559-21-98
NCGC00094796-01
NCGC00094796-02
QGUALMNFRILWRA-UHFFFAOYSA-M
SCHEMBL1477674
sodium [1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetate
Sodium 1-methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetate
Sodium 2-(1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl)acetate
Sodium tolmetin
Sodium tolmetin dihydrate
SPECTRUM1500582
Toleclin
TOLECTIN 600
TOLMETIN SODIUM
Tolmetin Sodium (anhydrous)
Tolmetin sodium [USAN:JAN]
Tolmetin sodium anhydrous
Tolmetin sodium salt
Tolmetin sodium salt dihydrate
Tolmetin Sodium, Anhydrous
UNII-WL259637KX
W-110866
WL259637KX

US Patents and Regulatory Information for TOLECTIN DS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ortho Mcneil Janssen TOLECTIN DS tolmetin sodium CAPSULE;ORAL 018084-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Merck
Chinese Patent Office
Mallinckrodt
US Department of Justice
Teva
Covington
Cantor Fitzgerald
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.